nCounter® Vantage 3D™ Solid Tumor Assays

Profile changes in DNA, RNA, and protein expression in a single experiment. The Vantage 3D DNA SNV and RNA:Protein Solid Tumor Assays are designed to provide a complete solid tumor profiling solution for both genotype and phenotype data.

  • Low sample inputs: as little as 5 ng DNA, 50 ng RNA, and 250 ng protein or just 2 FFPE slides.
  • Comprehensive profiling of key biological targets in Solid Tumor research: 104 actionable SNV and INDELS, 770 RNA, and up to 28 total and phospho-proteins
  • Integrated DNA, RNA, and protein measurements eliminate the challenge of comparing data from different technologies
  • Compatible with lysate and FFPE samples

Monitor targeted drug therapy response

Drug response to Vemurafenib (+/- Trametinib) was most pronounced in the homozygous BRAF V600E cell line yielding significant changes in gene and protein expression and intracellular phosphorylation state consistent with the mechanism of action of therapeutic kinase inhibitors.


Vantage 3D Profiling in FFPE Melanoma Samples

Targeted Drug Therapy Response

PDX Profiling

Vantage 3D DNA SNV Solid Tumor Panel

Simplify tumor characterization with detection of key cancer driver mutations.

Feature

Specifications

Number of Targets

104 SNV and INDELS covering 25 genes

Input Material

5 ng genomic DNA

Sample Type(s)

FFPE, fresh frozen tissue, cell extracts, cell lysates

Species

Human

Time to Results

<24 hours

Data Analysis

nSolver™ Analysis software

Shipping and Storage Conditions

-80°C (Amplification Reagents at -20°C)


Vantage 3D RNA:Protein Solid Tumor Assay for Lysate

Profile key cancer pathway targets at both the RNA, total protein, and phospho-protein level, including targets associated with PI3K, MAPK, EGFR, and more in your solid tumor tissue and cell lysates.

Feature

Specifications

Number of Targets

770 RNA, 28 proteins

Input Material

1 µg protein

Sample Type(s)

Cell lysates or fresh/frozen tissue lysates

Species

Human

Time to Results

<48 hours

Data Analysis

nSolver™ Analysis software

Customize

Up to 3 additional protein targets

Shipping and Storage Conditions

-80°C


Vantage 3D RNA:Protein Solid Tumor Assay for FFPE

FFPE-compatible profiling of key signaling pathways at the RNA, protein, and phospho-protein level with a modified protocol for your FFPE tissue.

Feature

Specifications

Number of Targets

770 RNA, 26 Proteins

Input Material

2 5 µM FFPE slides

Sample Type(s)

FFPE

Species

Human

Time to Results

<72 hours

Data Analysis

nSolver™ Analysis software

Customize

Up to 3 additional protein targets

Shipping and Storage Conditions

-80°C

Click here to view Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates.


Product

Description

Catalog Number

Unit Size

nCounter® Vantage 3D DNA SNV Solid Tumor Panel

Contains CodeSet for 104 solid tumor actionable mutations over 25 genes. Includes Pre-Amplification Reagents.

Note: this product is currently available on MAX/FLEX pre-qualified with the SNV Qualification kit.

VDXC-HST-12

12 reactions

nCounter® Vantage 3D RNA:Protein Solid Tumor for Lysates

770 gene expression CodeSet (PanCancer Pathways), Antibody Mix for 28 solid tumor signaling protein targets. Protein plus reagent (no ERCC) for protein target detection. Compatible with lysate samples.

VRPC-HSTL-12

12 reactions

nCounter® Vantage 3D RNA:Protein Solid Tumor for FFPE

770 gene expression CodeSet (PanCancer Pathways), 26 solid tumor signaling protein targets. Protein plus reagent (no ERCC) for protein target detection. Compatible with FFPE samples.

VRPC-HSTF-12

12 reactions

For Research Use Only. Not for use in diagnostic procedures.